Skip to main content

Table 1 Baseline sociodemographic and clinical characteristics of pediatric patients with COVID-19 and rheumatic diseases

From: Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases

Variable RMD COVID-19 patients
n = 77
RMD COVID-19 symptomatic patients
n = 47
RMD COVID-19 asymptomatic patients
n = 30
p value*
Women, n (%) 55 (71.43) 31 (65.95) 24 (80) 0.20
Age, mean (SD), years 11.88 (4.04) 12.04 (4.22) 11.63 (3.81) 0.53
Clinical remission, n (%) 52 (67.53) 28 (59.57) 24 (80) 0.37
Comorbidities 8 (10.39) 8 (17.02) 0 0.02
Diagnosis, n (%)     0.53
Chronic inflammatory arthritis
 Oligoarticular JIA 21 (27.27) 9 (19.14) 12 (40)  
 Oligoarticular JIA with associated uveitis 9 (11.69) 5 (10.63) 4 (13.33)  
 Polyarticular JIA 12 (15.58) 8 (17.02) 4 (13.33)  
 Enthesitis-related arthritis 4 (5.19) 3 (6.38) 1 (3.33)  
 Idiopathic uveitis 2 (2.60) 2 (4.25) 0  
Multisystemic autoimmune disorders
 Systemic lupus erythematosus 8 (10.38) 6 (12.76) 2 (6.66)  
 Scleroderma 1 (1.30) 1 (2.12) 0  
 Idiopathic inflammatory myopathy 3 (3.90) 2 (4.25) 1 (3.33)  
 Pediatric vasculitis 2 (2.60) 1 (2.12) 1 (3.33)  
Autoinflammatory diseases
 Systemic JIA 5 (6.49) 4 (8.51) 1 (3.33)  
 Chronic recurrent multifocal osteomyelitis 3 (3.90) 2 (4.25) 1 (3.33)  
 PFAPA syndrome 2 (2.60) 2 (4.25) 0  
 Monogenic autoinflammatory syndrome 5 (6.49) 2 (4.25) 3 (10)  
Rheumatic disease treatment, n (%)
 NSAIDs, n (%) 3 (3.90) 2 (4.25) 1 (3.33) 0.99
 Glucocorticoids, n (%) 9 (11.69) 7 (14.89) 2 (6.66) 0.46
 csDMARDsa, n (%) 35 (45.45) 22 (46.80) 13 (43.33) 0.81
 Ts/bDMARDsb, n (%) 40 (51.95) 24 (51.05) 16 (53.33) 0.99
  1. Abbreviations: CI Confidence Interval, SD standard deviation, JIA Juvenile idiopathic arthritis, NSAIDs Non-steroidal anti-inflammatory drugs, csDMARD Conventional synthetic disease-modifying anti rheumatic drugs, Ts/bDMARDs target synthetic/biologic disease-modifying anti rheumatic drug; a Methotrexate (n = 26), Hydroxychloroquine (n = 7), leflunomide (n = 2), Mycophenolate (n = 6), Azathioprine (n = 1), Cyclophosphamide (n = 1), Colchicine (n = 1). bAdalimumab (n = 11), Tocilizumab (n = 4), Canakinumab (n = 3), Etanercept (n = 15), Infliximab (n = 4), Rituximab (n = 1), Sarilumab (n = 1), Tofacitinib (n = 1)
  2. * p < 0.05